AlphaYou
Overview
Smart money at a glance
Filings to Sep 26, 2026Net buying: insiders sold $83K and bought $3M on the open market in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$2.9M netNet buying
- CongressSTOCK Act, last 180 days
- -$15K to -$50K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 4 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- 10+ awardsAwards on record
Key stats
Fundamentals Sep 25- Open
- $28.45
- 52-wk high
- $29.21
- High
- $28.69
- 52-wk low
- $22.09
- Low
- $28.17
- Prev close
- $28.41
- Mkt cap
- $161.93B
- P/E
- 36.9x
- Volume
- 27.76M
- Fwd P/E
- 9.7x
- Beta
- 0.30
- Div yield
- 6.10%
- P/S
- 2.5x
- P/B
- 1.9x
- Profit margin
- +6.8%
- Op margin
- +27.9%
- ROE
- +5.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about PFE filings
Are insiders buying or selling Pfizer Inc (PFE) stock?
Net buying: insiders sold $83K and bought $3M of PFE stock on the open market in the 90 days to Sep 26, 2026, according to SEC Form 4 filings. The largest was Bourla, Albert (Chairman & CEO), who bought $1M. The latest filing was on Aug 12, 2026.
Which members of Congress have traded PFE recently?
Sen. Thomas H Tuberville (R) sold $15K to $50K on Jun 8, 2026, disclosed 38 days later. In total, 1 member disclosed 1 PFE trade with trade dates in the last 180 days, filed a median 38 days after trading.
How current is this PFE smart-money data?
This summary uses filings available on Sep 26, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net buying.
What funds are doing
Buys/Adds (1)
- SU
Susquehanna
$124.4M
added
Sells/Trims (2)
- BA
Balyasny
$273.4M
trimmed
- DS
D.E. Shaw
$219.7M
trimmed
What insiders are doing
Buys (2)
- BA
Bourla Albert
$1.0M
bought
- BR
Blaylock Ronald E
$999K
bought
Sells (1)
- DJ
Damico Jennifer B.
$83K
sold
What Congress is doing
How top traders are positioned
No tracked top-trader positions in PFE right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 13.2% above what analysts expected.
Earnings per share
$0.68 expected
Revenue
$14.39B expected
GAAP EPS was -$0.04 and adjusted EPS was $0.77. The adjusted figure is comparable to consensus.
FY2026 guidance
$60.50B to $62.50B
No comparable estimate
Reports Nov 3, 2026, in 38 days
Estimates as of Sep 25, 2026
EPS expected
$0.59 to $0.94
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $16.65B | $17.56B | $14.45B | $15.03B |
| Cost of what it sold | $4.17B | $5.27B | $4.73B | $4.09B |
| Gross profit | $12.48B | $12.29B | $9.72B | $10.94B |
| What it spent | ||||
| Research and development | $3.94B | $3.42B | $2.63B | $2.81B |
| Sales and admin | $3.19B | $4.08B | $2.96B | $3.41B |
| Other operating costs | $1.81B | $1.10B | $100.0M | — |
| Total operating expenses | $8.93B | $8.60B | $5.69B | $6.24B |
| What was left | ||||
| Operating profit | $3.55B | $3.69B | $4.03B | $4.71B |
| Interest on debt | $652.0M | $711.0M | $668.0M | $667.0M |
| Profit before tax | $3.33B | -$1.64B | $3.17B | -$653.0M |
| Tax | -$216.0M | -$2.0M | $461.0M | -$407.0M |
| Net profit | $3.54B | -$1.65B | $2.69B | -$246.0M |
| EBITDA | $5.65B | $756.0M | $5.02B | $1.20B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study
BearishSep 23Top 10: Chief Digital Officers in Healthcare
Leans bullishSep 23Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone
Leans bearishSep 23Is Pfizer (PFE) Getting Too Pricey After Its 24% Rise?
Leans bearishSep 23AC Immune SA (ACIU) Stock Price, News, Quote & History
NeutralSep 22Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Andra AP fonden
NeutralSep 22Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
NeutralSep 22Why Is JNJ Stock Beating Rivals That Grow Faster?
NeutralSep 22
Macro
11 macro signals shaping PFE right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results